Transgenic Antithrombin (AT) Deficiency Product Launched

Transgenic Antithrombin (AT) Deficiency Product Launched

As a result of the approval of ATryn® (Antithrombin [Recombinant]) by the Food and Drug Administration, Lundbeck Inc. of Deerfield, IL, a subsidiary of H. Lundbeck A/S, is launching this product for patients in the US on May 6, 2009.

NBCA has produced a brochure entitled Antithrombin Deficiency: An In-Depth Guide for healthcare Providers and Patients, available in PDF on this website to make sure that both audiences are aware of this new treatment option. Click here to view the brochure.

Stephan Moll, MD, Medical Director, NBCA wrote the brochure, and sees it as an excellent resource to support the patients who live with this thrombophilia who may benefit from this product as one choice of therapy

“Lundbeck is excited to lead the launch of ATryn® in the United States,” stated Michael Burke, Chief Commercial Officer, Lundbeck Inc. “ATryn® is a unique product providing an important new treatment option for patients with hereditary antithrombin deficiency who are undergoing surgery or childbirth procedures.”

For additional information, Dr. Moll recommends the article Inherited antithrombin deficiency: a review (Patnaik) that can be found at the following link:https://www.stoptheclot.org/documents/inherited_antithrombin_deficiency.pdf

As a patient-led and scientific driven organization, NBCA takes it role to provide “hot off the press” treatment information to its constituents seriously.  The NBCA website already has information on how ATryn® was produced, that is easily found by looking for the photo of the goat, the source of ATryn®.

Lundbeck Inc. was previously known as Ovation Pharmaceuticals, Inc. prior to being acquired by H. Lundbeck A/S.

Click here to return to our news page.